Baijayantimala Swain | Pharmaceutical Medicinal Chemistry Award | Best Researcher Award

Posted on by ScienceFather

Dr. Baijayantimala Swain | Pharmaceutical Medicinal Chemistry Award | Best Researcher Award

Dr. Baijayantimala Swain, bharat institute of technology- pharmacy, India

Dr. Baijayantimala Swain is an accomplished medicinal chemist with expertise in drug design and discovery, specializing in carbonic anhydrase inhibitors. With a Ph.D. from NIPER Hyderabad, she has synthesized novel compounds targeting various isoforms of carbonic anhydrase, crucial in diseases like cancer and glaucoma. 🧪 Her research has led to the development of potent molecules with therapeutic potential. Dr. Swain’s multidisciplinary skills encompass organic synthesis, analytical techniques, and computational chemistry. She is recognized for her contributions to scientific literature and holds a strong academic background, fostering collaborative research in pharmaceutical sciences. 🎓

 

Publication Profile

Scopus

Academic Qualification 

Dr. Baijayantimala Swain forged her path in pharmaceutical sciences. From her Bachelor’s in Pharmaceutical Sciences at Sri Jaydev College in Odisha, India 🎓, she ventured into deeper realms with a Master’s in Medicinal Chemistry at NIPER, Hyderabad, delving into the intricacies of peptide synthesis for anticancer endeavors. Driven by an insatiable thirst for knowledge, she pursued a Ph.D. in Medicinal Chemistry at the same institute, where she honed her skills in designing novel inhibitors for carbonic anhydrases, under the guidance of esteemed mentors. Each milestone illuminated her academic odyssey, shaping her into a versatile researcher.

 

Research Focus 🧪

Dr. Baijayantimala Swain’s research primarily revolves around the design and synthesis of novel compounds targeting carbonic anhydrases, key enzymes involved in various physiological processes. Her work spans the development of diverse chemical entities, including sulfonamide and non-sulfonamide derivatives, ureidosulfocoumarin derivatives, and indole-based hybrids. These compounds hold promise as potential inhibitors of specific isoforms of carbonic anhydrases, with implications for therapeutic intervention in conditions such as cancer and other diseases. Through innovative approaches and meticulous experimentation, Dr. Swain contributes to the advancement of medicinal chemistry, striving to unlock new avenues for drug discovery and development.

 

Publication Top Notes 
  1. “Design, synthesis, and biological evaluation of 3-benzenesulfonamide-linked 3-hydrazinoisatin derivatives as carbonic anhydrase inhibitors” (2024)
  2. “Design, Synthesis and Biological Assessment of Rhodanine-Linked Benzenesulfonamide Derivatives as Selective and Potent Human Carbonic Anhydrase Inhibitors” (2022) – cited by 1
  3. “Synthesis of a new series of quinoline/pyridine indole-3-sulfonamide hybrids as selective carbonic anhydrase IX inhibitors” (2022) – cited by 7
  4. “Efficient One-pot Synthesis of 3,3-di(indolyl)indolin-2-ones from Isatin and Indole Catalyzed by VOSO4 as Non-Sulfonamide Carbonic Anhydrase Inhibitors” (2022) – cited by 1
  5. “Exploration of 2-phenylquinoline-4-carboxamide linked benzene sulfonamide derivatives as isoform selective inhibitors of transmembrane human carbonic anhydrases” (2022) – cited by 6
  6. “Design and development of novel series of indole-3-sulfonamide ureido derivatives as selective carbonic anhydrase II inhibitors” (2022) – cited by 5
  7. “Design and synthesis of benzenesulfonamide-linked imidazo[2,1-b][1,3,4]thiadiazole derivatives as carbonic anhydrase I and II inhibitors” (2021) – cited by 6